retatrutide glp-1 receptor agonist Scott Isaacs on X: "#retatrutide is a novel triple peptide at the glucagon receptor, GIP receptor, and receptor. 22-24% weight loss at 48 weeks with a similar tolerability profile to # retatrutide clinical trial updates 💊🔥

Based on Phase 2 trial protocols, retatrutide was typically initiated at 2 mg once weekly via subcutaneous injection

If you are taking GLP-1 medication for diabetes, continue monitoring your blood glucose as directed, though significant changes in glucose levels may not occur immediately

25 As data on their protective effects irrespective of LVEF are accumulating, international societies have recently expanded their recommended use to the entire spectrum of HF

Sherry Mattia Sherry is known as the glow-getter and is an expert at skin rejuvenation using the latest in anti-aging skin care treatments that restore your youthful appearance and make you feel amazing about yourself

Drugs.com

In REDEFINE 4, tirzepatide delivered 25.5% weight loss versus CagriSema at 23% over 84 weeks